US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Positive recommendation from the independent Data Safety Monitoring Board to continue Phase II Study

IBT announces that the second and last planned evaluation of safety data by the independent Data Safety Monitoring Board (DSMB), in the ongoing Phase II clinical study, was performed on November 18th. The DSMB concluded that there were no objections to dose escalation into the final cohort of the smallest  premature babies, who will be dosed with the highest dose of IBT´s drug candidate IBP-9414.  "We are very pleased that we now have 90 of the 120 premature babies recruited and that the study is progressing according to plan. This is another major milestone in the development of a new

Infant Bacterial Therapeutics AB appoints new CFO

Infant Bacterial Therapeutics AB (publ.) (“IBT”) is pleased to announce the appointment of Daniel Mackey as Chief Financial Officer (CFO) from January 2017 replacing Michael Owens in this role. Michael Owens will continue as financial controller of the company. Daniel has 20 years experience from diverse U.S. and international management positions in finance and accounting with Investors Bank & Trust Co., Nordea Investment Management AB and Nordea Bank AB.  In his role as CFO, Daniel will be responsible for overseeing capital and financing strategies, accounting and investor relations.

Infant Bacterial Therapeutics AB (publ), (IBT) Interim report January 1 – June 30 2016

Message from the CEO “In June we announced that the first premature infant had been enrolled and dosed in the Company´s Phase ll clinical trial. This Phase ll trial is a randomized, double blind, parallel group, dose escalation, placebo-controlled multicenter study to investigate the safety and tolerability of IBP-9414 administered in preterm infants. The multicenter trial is being conducted in a number of neonatal intensive care units in the US and will enroll 120 premature infants in total. The first planned independent Data Safety Monitoring Board (DSMB) evaluation of safety data was

Infant Bacterial Therapeutics enrolls First Patient in Phase 2 Clinical Trial

Infant Bacterial Therapeutics AB (publ) (“IBT”) announces that the first premature infant has been enrolled and dosed in the Company´s Phase 2 clinical trial. This Phase 2 trial is a randomized, double blind, parallel group, dose escalation, placebo-controlled multicenter study to investigate the safety and tolerability of IBP-9414 administered in preterm infants. This is the first trial in the clinical development of IBP-9414 for the prevention of the often fatal disease necrotizing enterocolitis which affects premature infants. The multicenter trial is being conducted in a number of

Infant Bacterial Therapeutics receives Rare Pediatric Disease Designation from FDA for drug candidate

Infant Bacterial Therapeutics AB (publ) (“IBT”) announces that the U.S. Food and Drug Administration (FDA) has awarded IBT Rare Pediatric Disease Designation for its drug candidate IBP-9414, intended for the prevention necrotizing enterocolitis in premature infants. Rare Pediatric Disease Designation is intended to encourage development of new drug and biological products for the prevention and treatment of certain rare pediatric diseases. Having obtained the Rare Pediatric Disease Designation, FDA may award IBT a priority review voucher. A priority review voucher means that FDA ought to

Infant Bacterial Therapeutics is listed on Nasdaq First North and publishes company description

Infant Bacterial Therapeutics AB (publ) (“IBT”) has been approved for listing and the company’s series B shares will be traded on Nasdaq First North as from 29 March 2016 with Erik Penser Bankaktiebolag as Certified Adviser. The listing is part of the distribution of all of BioGaia AB’s (publ) shares in IBT to BioGaia’s shareholders, which was resolved at the extraordinary general meeting of BioGaia on 18 March 2016. A company description has been prepared in connection with the listing and is available on IBT’s website, www.ibtherapeutics.com For additional information please contact

There are no items matching the current filter
There are no more items matching the current filter
Back to top